Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

$18.67 Bn MASH Treatment Market Trends, Opportunities and Strategies, 2019-2024, 2025-2029 & 2034

globenewswire.com
MDGL Madrigal Pharmaceuticals Inc. is identified as a leading player in the MASH treatment market, holding a significant 6.93% share. The overall market is projected for substantial growth, indicating positive prospects for key companies like Madrigal. NVO Novo Nordisk A/S is mentioned as one of the leading players in the MASH treatment market. While the market is expected to grow significantly, the article does not provide specific details on Novo Nordisk's performance or future outlook within this market. LLY AZN AstraZeneca plc is named as one of the top players in the MASH treatment market. The article indicates a positive growth trajectory for the market overall, but lacks specific details regarding AstraZeneca's individual performance or future prospects.

Dublin, Jan. 05, 2026 (GLOBE NEWSWIRE) -- The "MASH Treatment Market Opportunities and Strategies to 2034" has been added to ResearchAndMarkets.com's offering.

The comprehensive analysis of the MASH (Metabolic Associated Steatohepatitis) treatment market projects significant growth from 2019 through 2034, with the market valued at $2.59 billion in 2024. This reflects a robust CAGR of 21.55% since 2019. Forecasting to 2029, the market is anticipated to expand further to $7.04 billion, achieving a CAGR of 22.09%. Growth is set to continue, projected to reach $18.67 billion by 2034 at a CAGR of 21.53%.

Market expansion during the historic period was fueled by investments in R&D, a surge in personalized medicine demand, active government support, and increased global health awareness. However, stringent regulatory frameworks and limited public awareness impacted growth. Looking ahead, drivers such as the rising incidence of non-alcoholic fatty liver disease (NAFLD), demand for liver transplants, and obesity prevalence are poised to accelerate the market. Challenges may arise from high treatment costs, limited biomarker access, and geopolitical trade implications.

Regionally, North America led the market in 2024 with a 46.13% share, totaling $1.19 billion. Asia Pacific followed, and it, along with North America, is expected to exhibit the fastest growth with respective CAGRs of 27.73% and 20.93%. Africa and South America will also show notable expansion with CAGRs of 19.47% and 19.15%.

The MASH treatment market is competitive but fragmented, with the top 10 players accounting for 9.15% of the market in 2024. Leading the way, Madrigal Pharmaceuticals Inc. held a 6.93% share, followed by entities such as Novo Nordisk A/S, Eli Lilly Company, and AstraZeneca plc.

Segmenting by treatment, the drug segment dominated in 2024, contributing 78.58% ($2.04 billion) of market value, and it's poised to continue as the fastest-growing segment through 2029 with a CAGR of 22.87%. By end-user, hospitals were the largest segment, comprising 49.09% ($1.27 billion) of 2024's total. Specialty clinics, however, will become the fastest-growing end-user segment, registering a 23.56% CAGR over the forecast period.

Among the disease stages, early MASH (significant/advanced fibrosis) accounted for the largest share at 34.83% ($904.74 million) in 2024, anticipated to lead future growth with a 27.12% CAGR from 2024 to 2029.

Market opportunities are substantial, with the drug segment projected to achieve an additional $3.67 billion by 2029. Hospitals will dominate end-user gains at $2.08 billion, with significant opportunities also in the early MASH stage at $2.09 billion.

Strategically, the market emphasizes advancing fibroblast growth factor, integrating AI for precision in treatment, securing regulatory approvals, and fostering strategic partnerships for growth. Companies are encouraged to leverage these strategies, focusing on emerging markets while maintaining a foothold in developed regions to maximize market reach and innovation.

Chapters Covered:

Markets Covered:

Key Attributes:

Companies Featured

For more information about this report visit https://www.researchandmarkets.com/r/ubs4ek

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment